Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation

The activation mechanism of chimeric antigen receptor (CAR)-engineered T cells may differ substantially from T cells carrying native T cell receptor, but this difference remains poorly understood. We present the first comprehensive portrait of single-cell level transcriptional and cytokine signatures of anti-CD19/4-1BB/CD28/CD3ζ CAR-T cells upon antigen-specific stimulation. Both CD4+ helper T (TH) cells and CD8+ cytotoxic CAR-T cells are equally effective in directly killing target tumor cells and their cytotoxic activity is associated with the elevation of a range of TH1 and TH2 signature cytokines, e.g., interferon γ, tumor necrotic factor α, interleukin 5 (IL5), and IL13, as confirmed by the expression of master transcription factor genes TBX21 and GATA3. However, rather than conforming to stringent TH1 or TH2 subtypes, single-cell analysis reveals that the predominant response is a highly mixed TH1/TH2 function in the same cell. The regulatory T cell activity, although observed in a small fraction of activated cells, emerges from this hybrid TH1/TH2 population. Granulocyte-macrophage colony stimulating factor (GM-CSF) is produced from the majority of cells regardless of the polarization states, further contrasting CAR-T to classic T cells. Surprisingly, the cytokine response is minimally associated with differentiation status, although all major differentiation subsets such as naïve, central memory, effector memory, and effector are detected. All these suggest that the activation of CAR-engineered T cells is a canonical process that leads to a highly mixed response combining both type 1 and type 2 cytokines together with GM-CSF, supporting the notion that polyfunctional CAR-T cells correlate with objective response of patients in clinical trials. This work provides new insights into the mechanism of CAR activation and implies the necessity for cellular function assays to characterize the quality of CAR-T infusion products and monitor therapeutic responses in patients.

[1]  Leroy Hood,et al.  Systems Approaches to Biology and Disease Enable Translational Systems Medicine , 2012, Genom. Proteom. Bioinform..

[2]  Takashi Saito,et al.  CD4 CTL, a Cytotoxic Subset of CD4+ T Cells, Their Differentiation and Function , 2017, Front. Immunol..

[3]  Sylvain Julien,et al.  Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor1 , 2008, The Journal of Immunology.

[4]  V. Singer,et al.  Fluorescence microplate-based assay for tumor necrosis factor activity using SYTOX Green stain. , 2001, Analytical biochemistry.

[5]  Petra Reinke,et al.  Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells , 2017, The Journal of Immunology.

[6]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[7]  J. Bluestone,et al.  Is autoimmunity the Achilles' heel of cancer immunotherapy? , 2017, Nature Medicine.

[8]  Alexander van Oudenaarden,et al.  Stochastic Cytokine Expression Induces Mixed T Helper Cell States , 2013, PLoS biology.

[9]  Burkhard Becher,et al.  GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. , 2016, Immunity.

[10]  R. Orentas,et al.  Towards a commercial process for the manufacture of genetically modified T cells for therapy , 2015, Cancer Gene Therapy.

[11]  D. Pe’er,et al.  Highly multiplexed profiling of single-cell effector functions reveals deep functional heterogeneity in response to pathogenic ligands , 2015, Proceedings of the National Academy of Sciences.

[12]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[13]  David Klatzmann,et al.  CD4+CD25+ Immunoregulatory T Cells , 2002, The Journal of experimental medicine.

[14]  Wei Lin,et al.  Single-cell Transcriptome Study as Big Data , 2016, Genom. Proteom. Bioinform..

[15]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[16]  Thomas Höfer,et al.  Stable T-bet+GATA-3+ Th1/Th2 Hybrid Cells Arise In Vivo, Can Develop Directly from Naive Precursors, and Limit Immunopathologic Inflammation , 2013, PLoS biology.

[17]  H. Huls,et al.  Driving CAR-Based T-Cell Therapy to Success , 2014, Current Hematologic Malignancy Reports.

[18]  Christine E Brown,et al.  Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.

[19]  Richard A Flavell,et al.  Producing GM-CSF: a unique T helper subset? , 2014, Cell Research.

[20]  Rong Fan,et al.  Annual Review of Biomedical Engineering Single-Cell Omics Analyses Enabled by Microchip Technologies , 2019 .

[21]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[22]  Burak Dura,et al.  Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation , 2019, Nature Communications.

[23]  Sean C. Bendall,et al.  viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia , 2013, Nature Biotechnology.

[24]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[25]  Michel Sadelain,et al.  CD19 CAR T Cells , 2017, Cell.

[26]  Alexander E Kalyuzhny,et al.  Chemistry and biology of the ELISPOT assay. , 2005, Methods in molecular biology.

[27]  Andreas Radbruch,et al.  Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions. , 2010, Immunity.

[28]  Jonathan J. Chen,et al.  JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. , 2015, Cancer discovery.

[29]  Michel Sadelain,et al.  PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses , 2013, Science Translational Medicine.

[30]  Rong Fan,et al.  Analysis of single-cell cytokine secretion reveals a role for paracrine signaling in coordinating macrophage responses to TLR4 stimulation , 2015, Science Signaling.

[31]  Yang Feng,et al.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. , 2016, The Journal of clinical investigation.

[32]  David Klatzmann,et al.  Immunoregulatory T Cells : New Therapeutics for Graft-Versus-Host Disease , 2002 .

[33]  D. Maloney,et al.  Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. , 2014, Cancer journal.

[34]  Alaina Kaiser,et al.  Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. , 2018, Blood.

[35]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[36]  Ivan Liadi,et al.  Abstract 4745: Quantitative single-cell functional characterization of CD19-specific CAR+ T Cells for immunotherapy. , 2013 .

[37]  V. Golubovskaya,et al.  Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy , 2016, Cancers.

[38]  John P. Puccinelli,et al.  Thermal aging and reduced hydrophobic recovery of polydimethylsiloxane , 2006 .

[39]  Michel Sadelain.  CAR therapy: the CD19 paradigm. , 2015, The Journal of clinical investigation.

[40]  Michel Sadelain,et al.  Therapeutic T cell engineering , 2017, Nature.

[41]  Alaina Kaiser,et al.  Abstract 2990: Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin’s lymphoma , 2017 .

[42]  Alaina Kaiser,et al.  Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response , 2017, Journal of Immunotherapy for Cancer.

[43]  Makoto Murata,et al.  Exhaustion of CMV Specific T Cells with Enhanced PD-1 Expression In Persistent Cytomegalovirus Infection After Allogeneic Stem Cell Transplantation , 2010 .

[44]  Burak Dura,et al.  scFTD-seq: freeze-thaw lysis based, portable approach toward highly distributed single-cell 3′ mRNA profiling , 2018, Nucleic acids research.

[45]  Fan Yang,et al.  STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation , 2014, Cell Research.

[46]  Evan Z. Macosko,et al.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets , 2015, Cell.

[47]  Bruce L Levine,et al.  PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. , 2017, Blood.

[48]  Yu Wu,et al.  High-throughput secretomic analysis of single cells to assess functional cellular heterogeneity. , 2013, Analytical chemistry.